NCT03030378 2026-03-18
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
29 trialsNCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04317105 2026-03-18
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05327010 2026-03-18
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05372614 2026-03-18
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05554341 2026-03-18
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05554380 2026-03-18
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05687110 2026-03-18
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05687136 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05691517 2026-03-18
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06606990 2026-03-18
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04585958 2026-03-17
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05638295 2026-03-17
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06311214 2026-03-06
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04294628 2026-02-27
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06320405 2025-12-29
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT06043713 2025-12-19
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT03872427 2025-11-14
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06207864 2025-11-13
PE-CGS
New Mexico Cancer Research Alliance
Phase NA Recruiting
NCT06911008 2025-11-10
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Mayo Clinic
Phase 1 Recruiting
NCT06962995 2025-10-24
Multi-Cancer Detection Observational Cohort Study
Mayo Clinic
Recruiting
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02079740 2025-09-30
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT06223542 2025-09-29
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07131007 2025-09-04
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics
Hebei Medical University Fourth Hospital
Not yet recruiting
NCT05733949 2025-06-17
Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors
City of Hope Medical Center
Phase NA Recruiting
NCT05530759 2025-04-02
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
Mayo Clinic
Recruiting
NCT06832150 2025-02-18
SMS2
The Wellcome Sanger Institute
Enrolling by invitation
NCT05653661 2025-01-07
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Mayo Clinic
Phase 1 Withdrawn